Blood-based Monitoring for the Diagnosis and Prognosis of Melanoma

Address to event

Harvard Medical School, Tosteson Medical Education Center, Room 227
260 Longwood Avenue
Boston, MA

HSCI Skin Program Meeting (all members of the HSCI research community are welcome)

Guest speaker:
Mel Ziman, PhD

Prof Mel Ziman is the Associate Dean of Research in the School of Medical and Health Sciences, Leader of the Melanoma Research Group, and Chair of the University Human Research Ethics Committee at Edith Cowan University in Perth, Western Australia.

Prof Ziman and her team have secured continuous funding for their melanoma research since 2010 with over $8 million dollars from state and federal national funding agencies and international pharmaceutical and biotechnology companies.

Prof Ziman is chair and member of the scientific advisory boards of the Cancer Council of Western Asutralia, and a member of the Australian Parliamentary Standing Committee on Skin cancer. She has been awarded a Vice Chancellery Excellence Award for her Research and been a member of the Australian National Health and Medical Research Council (NHMRC) grant review panel since 2010. She frequently reviews grants for national and international agencies, articles for high impact journals and theses for high-ranking universities in Australia.  Prof Ziman has published over 140 papers with over 2000 citations, and been an invited speaker at 85 international and national conferences in the past 10 years.

The Melanoma Research Group that she leads at Edith Cowan University have developed blood tests for the diagnosis and prognosis of melanoma in collaboration with world leading clinicians, researchers and biotechnology companies. The tests are the subject of patent applications and have been, in some cases, adopted for routine clinical testing in Western Australia. The adoption of these tests worldwide will assist with melanoma detection and monitoring to improve patient outcomes.

Go to Event Web Page